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ABSTRACT

OBJECTIVE: The objectives of this selective EBM review is to determine whether or not
Autologous Chondrocyte Implantation is more effective than microfracture in the repair
of articular knee defects.
STUDY DESIGN: Review of three English language primary studies published in 2009
and 2010.
DATA SOURCES: Randomized controlled trials comparing Autologous Chondrocyte
Implantation and Microfracture found using PubMed, MedLine and Cochrane Database.
OUTCOMES MEASURED: Clinical outcome measured by the Knee Injury and
Osteoarthritis Outcome Score (KOOS). The primary measure of outcome was evaluated
using the KOOS questionnaire with subdomains of ADL’s, pain, symptoms, stiffness and
quality of life. KOOS data was compared between treatment groups for patients with
symptom onset less than 2 years vs more than 2 years and less or more than 3 years.
Serial MRI scans were scored using Magnetic resonance Observation of Cartilage Repair
Tissue (MOCART) system. A rehabilitation protocol was implemented where
components were evaluated pre surgery and at 6, 9, 12 and 24 months post surgery.
Patients are followed up 8-12, 22-26, 50-54 weeks post operatively for efficacy and
safety evaluations.
RESULTS: Three randomized controlled trials were included in this review. The study
by Basad indicated ACI as having significantly more effective outcomes over 2 years
compared to microfracture. Saris’ study provided similar conclusions, offering improved
outcomes with ACI after 36 months. However, Van Assche’s study had similar overall
functional outcomes for both ACI and MF.
CONCLUSIONS: Based on findings upon analysis of three RCT’s, Autologous
chondrocyte implantation provides significant improvement in articular knee defects
allowing improved function, mobilitiy and activity as compared to that of microfracture.
KEY WORDS: Autologous chondrocyte implantation, microfracture
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Introduction:
ACI is an advanced cell based technique for treatment of cartilage defects. Damage to
the articular cartilage limits activity level as well as the ability for reparation and
restoration of the knee. Intact articular cartilage is needed for normal joint movement and
decreased friction through range of motion. The first stage of autologous chondrocyte
implantation begins with arthroscopic sampling of cartilage from an area of limited
weight bearing, typically from the medial or lateral femoral condyle1. Chondrocytes are
then isolated where they can then be grown in vitro for 4 to 6 weeks2. An area of the
periosteum is then harvested and formed into a periosteal patch that will be sutured over
the area of damaged cartilage3. A tight seal will be formed so that once the cells are
reimplanted they will be held in place at the site of injury3. The cells are then reimpanted
into the damaged area of articular cartilage through arthrotomy. The autologous cells will
adapt by forming new cartilage into the area of the defect3.
ACI is an appropriate treatment for small tears of the cartilage. It is not to be used for
widespread wear of the cartilage such as with arthritis1. The patient must have a stable
knee without associated ligament damage, must be of healthy BMI and have failed with
nonoperative treatments1. Femoral condyle injuries are very common in athletes and ACI
can be an effective technique for repair in the field of orthopedic surgery. This is
especially useful for patients opting out of total knee replacements. The total cost for the
ACI procedure falls between $17,600 and $38,4006. A patient of ACI would have
multiple healthcare visits yearly due to the preoperative imaging needing to visualize the
level of damage, the 2 steps in the procedure, where 6 weeks after the cells are taken the
patient will have them reimplanted, as well as the post op follow up imaging and physical
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exam along with necessary physical therapy. Follow up visits vary depending on level of
pain, range of motion and disability levels. Articular cartilage defects are often due to
sports related trauma. Due to its avascular nature it has poor ability to repair itself. Focal
articular cartilage defects are often the source of pain and functional issues and so early
diagnosis is important in appropriate management10. Articular defects if untreated can
lead to additional injuries including menisci and cruciate ligament injuries10.
First line treatment typically includes debridement and lavage by which
loose articular tissue debris is removed10. However, such management may solely have
short term effects. Microfracture is another technique that is frequently used.
Subchondral bone is disrupted in an attempt to initiate stem cell migration to the site of
the defect10. Conservative treatments should always primarily be used. These include
NSAID use, steroid injections, physical therapy11. Patients with severe injury may
undergo total knee replacements where prosthetic tibial, femoral and posterior patellar
surfaces are implanted11.
ACI is an appropriate treatment for small tears of the cartilage. It is not to
be used for widespread wear of the cartilage such as with arthritis. It is a promising new
treatment for full thickness articular cartilage defects. ACI restores the cartilage whereas
microfracture simply covers up the defect.
Objective: The objective of this selective EBM review is to determine whether or not
ACI is more effective than microfracture in the repair of articular cartilage knee injuries.
Methods: The chosen studies were all randomized controlled trials. The populations
included were patients with symptomatic cartilage defects of the knee. The interevention
of Autologous Chondrocyte Implantation was compared to Microfracture. Measured
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outcomes include level of function, range of motion, mobility, strength, stiffness and
activity of daily life. A detailed search was completed through use of search engines
Pubmed, MedLine, and Cochrane database. Keywords “Autologous chondrocyte
implantation” and “Microfracture” were used in combination to search for Englishlanguage articles. All of the resulting qualified articles were published between 2009 and
2010 in peer reviewed journals. The patients included people between the ages of 18 and
50 with articular knee injuries. Excluded however were people with the presence of
inflammatory arthritis, instability of the knee joint, prior or planned meniscectomy of
over 30% of the meniscus, BMI >30, varus or valgus deformity, osteonecrosis,
osteoarthritis or chondrocalcinosis. For this review, selected dichotomous data were
interpreted by using statistics including P-values, NNT, RRR and ARRR.
Table 1 - Demographics & Characteristics of included studies
Study
Type #
Age
Inclusion criteria
Exclusion
of
(yrs)
criteria
Pts
RCT 60 18-50 -Symptomatic
The prescence of
Basad,
cartilage defects
chronic inflammatory
Ehran, 2010
-Post traumatic
arthiritis, instability
-Single isolated
of the knee joint,
chondral defects of
prior or planned
the femoral condyle
meniscectomy of
or patella.
over 30 % of the
meniscus, BMI
greater than 30, varus
or valgus deformity,
osteonecrosis,
osteoarthritis or
chondrocalcinosis.
Saris, Daniel, RCT 118 18-50 Single International
Cartilage Repair
No exclusion criteria
2009
Society grade III/IV
noted
symptomatic
cartilage defects of
the femoral condyles
in a stable, well

W/D

Intervention

3

Microfracture

33

Microfracture
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Van Assche,
2009

RCT

67

18-50

aligned knee with
minimal additional
injury, agreeing to
comply with a strict
rehabilitation
protocol
-Local cartilage
defects w mean size
2.4 cm of the femoral
condyle of the knee

13

Microfracture

No exclusion criteria
noted

-Symptomatic single
cartilage lesions of
the femoral condyle
between 1 and 5 cm
-Agreed to actively
participate in strict
rehabilitation and
follow up programs.

Outcomes Measured:
Clinical outcome measured by the Knee Injury and Osteoarthritis Outcome Score
(KOOS). The primary measure of outcome was evaluated using the KOOS questionnaire,
a validated self reported assessment consisting of 5 separately scored subdomains:
ADL’s, pain, symptoms, stiffness and quality of life. KOOS data was compared between
treatment groups for patients with symptom onset less than 2 years v. more than 2 years
and less or more than 3 years. Serial MRI scans were scored using Magnetic resonance
Observation of Cartilage Repair Tissue (MOCART) system. MRI scans were taken 1
week post operatively to check for delamination and graft hypertrophy. A rehabilitation
protocol was implemented for both active knee flexion and extension range, anterior
laxity, knee extension strength and single leg hop performance. All were evaluated pre
surgery and at 6, 9, 12 and 24 months post surgery. Patients are followed up 8-12, 22-26,
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50-54 weeks post operatively for efficacy and safety evaluations. Tegner scores are taken
for activity level, Lysholm scores for pain, stability, gait and clinical symptoms. ICRS
scores were also used.
Results:
Three Randomized Controlled Trials were used to compare the outcomes of
chondral knee defects upon the use of ACI versus MF.
Van Assche’s study used a significant level set at P<0.05 and confidence interval
of 95 %. Active knee flexion improved for both groups, but extension and anterior laxity
remained unchanged. Single hop performance was improved more so with MF than ACI.
At 6 months both groups had decreased functional performance, but because it was less
pronounced in those with MF, these patients recovered to pre-surgery levels of
performance at 9 months. However, both groups had small yet significant outcomes
between 12 and 24 months. Most importantly, functional recovery at 2 years is
comparable for both groups. Patients with recent osteochondritis dissecans, advanced
osteoarthritis, ligament instability and malalignment greater than 5 degrees were
excluded. The Number Needed to Treat was calculated to be 4.76, therefore for every 5
patients, 1 more patient had improved outcomes compared to the control (Table 2).
However, the Number Needed to Harm was 16.67, so for every 17 patients 1 person
worsened compared to the control group (Table 3)
In Basad’s study there were no significant differences except symptom duration
which was .3 years longer in the Microfracture group. The difference between baseline
and 2 years post operatively for Lysholm scores for both groups were significant with a
P<.0001. However, the ACI group was more effective over time with a P = 0.005. The
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Lysholm score rates a patients pain, swelling, mobility, limp, locking sensation, squatting
ability, stair climbing ability, and giving out sensation on a scale. Tegner scores were also
monitored which measures the patients activity level. This is measured preoperatively
and postoperatively. ACI (P < 0.0001) was also significantly more effective over time
than MF (P=0.04). Patients with osteochondral defects were withdrawn and 3 patients
dropped out; One without reason, one became pregnant and the other was an early
treatment failure. Significance level was set a 5 %. The Number Needed to Treat was 100
therefore, for every 100 people treated with ACI, 1 more patient had improved outcomes
compared to the control group (Table 2).
Saris’ study did not provide enough information to convert to dichotomous data
because the outcomes measured were unable to be categorized into two mutually
exclusive groups. The median duration of symptoms was longer for patients receiving
ACI than MF. ACI patients symptoms lasted nearly 2 years whereas MF patients lasted
about a year and a half. Mean improvements of ADL’s, pain, symptoms, stiffness, quality
of life and sports were all greater in the ACI group. At 36 months, more patients
responded to ACI for KOOS responder analysis. KOOS represents the Knee Injury and
Osteoarthritis Outcome Score.
Table 2. Efficacy of ACI in Treatment of Chondral Defects: NNT
Study

Control
Event Rate
(CER)

Basad, 2010
Saris, 2009
Van Assche,
2009

.09%
N/A
.62%

Experimental Relative
Event Rate
Benefit
(EER)
Increase
(RBI)
.1%
.111%
N/A
N/A
.83%
.339%

Absolute
Benefit
Increase
(ABI)
.01%
N/A
.21%

Number
Needed to
Treat (NNT)
100
N/A
4.76
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Table 3. Efficacy of ACI in Treatment of Chondral Defects: NNH
Study
Control
Experimental
Relative Risk Absolute
Event Rate
Event Rate
Increase
Risk
Increase
Van Assche, .82%
.88%
.073%
.06%
2009

Number
Needed to
Harm
16.67

Saris’ study provides plentiful data on safety assessment. 67% of people receiving
ACI treatment and 59% of MF patients experienced at least one adverse effect over the
entire 36 months of recovery. However, these numbers decreased to 32% and 33%
respectively from 18 months to 36 months. Majority of adverse effects were mild to
moderate yet 25% of both ACI and MF patients experienced at least one severe adverse
effect. More patients receiving Microfracture experienced a significant adverse effect
than did those with ACI. Arthralgia was the most common adverse event for both groups.
However, patients with ACI had more joint swelling, crepitus and cartilage hypertrophy.
3 patients of the Microfracture group withdrew due to their undesirable outcomes,
whereas no patients of ACI were discontinued for such reasons.
Basad’s study provided no treatment related safety issues and any irritation
experienced was eased through the use of NSAIDs. One patient in the ACI group had
persistent pain after one year.
The study created by Van Assche mentions a limitation in which the patients as
well as the physical therapists were not blinded to the treatment allocation. Future studies
could overcome this by at least blinding the assessor to the knee of injury. One could do
so simply by keeping the knees covered during treatment.
Discussion:
Controversy still exists as to whether Microfracture or Autologous Chondrocyte
Implantation is the best repair technique. Injuries they should be used for are also still
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being investigated. Many attempts to repair damaged articular cartilage have been met
with issues such as inability to produce hyaline cartilage, poor integration with the
surrounding cartilage, and gradual deterioration of the repair tissue8. ACI was first used
in 1987 and has been performed on more than 12,000 patients internationally8. Carticel is
currently the only FDA approved technique for culturing of chondrocytes4. In 1997,
Carticel received FDA approval for the repair of clinically significant, symptomatic
cartilaginous defects of the femoral condyle caused by acute or repetitive trauma4.
ACI has demonstrated significant benefits for patients in terms of diminished pain
and improved function. This treatment however continues to be very strictly regulated. It
is currently the most widely researched clinical cartilage repair technique. Despite the
fact that ACI has been in clinical use for more than 15 years, the evidence for the
outcomes is lacking. Although this may be the procedure of the future, it does still have
downsides including the potential leakage of chondrocytes from defects, the uneven
distribution of cells, and the risk of periosteal complications8. Early problems include
periosteal graft detachment and delamination as well as late periosteal hypertrophy8.
When repairing articular defects it is important to initially diagnose and correct any
significant comorbities such as meniscus injury, ligament laxity, or malalignment of the
tibiofemoral or patellofemoral joint8. Uncorrected meniscal deficiency and ligament
laxity are a contraindication to cartilage restoration procedures. The ACI procedure is
predominantly for lesions larger than 2 cm8. Over 100 payers have medical policies that
cover Carticel, including Cigna, Prudential, and United Healthcare. Over 50% of the 43
independent Blue Cross and Blue Shield Association members representing 25 States
allow coverage for ACI9.

Manzouri, ACI in Repair of Articular Defects, 9
Conclusion:
Although there is conflicting evidence in the current literature, 2 of the 3 RCT’s
indicate improved outcomes with ACI as compared to MF. Both Saris and Basad’s
studies demonstrated significantly better treatment in symptomatic articular defects.
Therefore, I agree with such studies in that ACI provides improved function, mobility
and activities of daily life moreso than with treatment with Microfracture. va
Autologous chondrocyte implantation is used to repair defects in the articular
cartilage. When the cartilage is injured the chondrocytes lose their ability to regenerate
causing loss of function and often immobility. With ACI, chondrocytes are taken from
nonweight bearing portion of the femur, sent to a lab and cultured for reimplantation. 6
weeks later new chondrocytes are implanted into the patient at the site of the articular
cartilage injury1. The 2 primary goals for an ACI rehabilitation program are adaptation
and remodeling of the repair as well as return to function8. The 3 main components of the
rehabilitation program are progressive weightbearing, restoration of range of motion, and
enhancement of muscle control and strengthening8. The repair site is at its most
vulnerable during the first 3 months after ACI8. At this time, it is important to avoid
impact as well as excessive loading and shearing forces. It is difficult to assess the
effectiveness of ACI and its long-term results however many studies are underway in
search of answers. Research is lacking in terms of force such grafts can endure. Future
studies should focus on the stresses necessary to disrupt or delaminate the graft. ACI
could be the treatment of the future as it will reduce the surgical morbitidy associated
with open arthrotomy8.
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